Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07624526 · ClinicalTrials.gov registry record · Phase 4
Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
A Phase 4 study, sponsored by Emory University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT07624526 is a Phase 4 study that has not yet begun recruiting, run by Emory University. The registered enrollment target is 75 participants.
The verdict
NCT07624526, a Phase 4 study, has not yet begun recruiting, sponsored by Emory University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.
Interventions
- DRUG Suzetrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07624526
The ClinicalTrials.gov registry entry for NCT07624526 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Suzetrigine is the first listed.
NCT07624526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07624526 about?
NCT07624526 is a clinical study titled "Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty". This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in additi...
What is the current status of trial NCT07624526?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2026-07. Estimated completion is 2028-08.
What interventions are being tested in trial NCT07624526?
The interventions under investigation include: Suzetrigine (DRUG).
Who is sponsoring clinical trial NCT07624526?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.